ImmunoCellular Therapeutics Names New CEO
December 16, 2016
ImmunoCellular Therapeutics (Los Angeles, CA) announced that its Board of Directors has appointed Anthony Gringeri, Ph.D, as Chief Executive Officer. The appointment follows the decision by Andrew Gengos to resign the position of CEO. Mr. Gengos will continue to play an active role with the company as a member of the Board of Directors, the company reports. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer. He previously served as Chief Operating Officer for Amsterdam Molecular Therapeutics.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
